摘要
随着肿瘤分子病理学和分子生物学研究的不断深入,靶向药物治疗已经成为肿瘤综合治疗策略中重要的组成部分。相比手术、放疗和化疗这些传统的治疗方式,靶向治疗在适合的患者中,具有效果更好、毒性低的特点,可以提高患者的生存质量,其临床效果愈加显现。本文就近年来CD20、EGFR单克隆抗体等在治疗晚期口腔颌面头颈部肿瘤中的应用进行述评。
With the development of molecular pathology and molecular biology of tumors,targeted drug therapy has become an important part of comprehensive tumor treatment strategy.Compared with the traditional methods of surgery,radiotherapy and chemotherapy,targeted drug therapy is more effective and less toxic,and improves the quality of life of patients.Its clinical effects are more obvious.In this paper,the recent progress of CD20 and EGFR monoclonal antibodies in the treatment of advanced oral and maxillofacial head and neck tumors are reviewed.
作者
郭伟
GUO Wei(Department of Oral Maxillofacial-Head Neck Oncology,the Ninth People's Hospital,Shanghai Jiao Tong University School of Medicine,National Clinical Research Center for Oral Diseases,Shanghai 200011,China)
出处
《口腔颌面外科杂志》
CAS
2020年第3期132-136,共5页
Journal of Oral and Maxillofacial Surgery
基金
上海市科学技术委员会科研资助项目(11495802000、14DZ1941400、10410711200)。
关键词
述评
临床应用
靶向治疗
口腔颌面头颈部恶性肿瘤
comment
clinical application
targeted therapy
oral and maxillofacial-head and neck malignancy
